HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

Correale, Pierpaolo; Saladino, Rita Emilena; Giannarelli, Diana; Sergi, Andrea; Mazzei, Maria Antonietta; Bianco, Giovanna; Giannicola, Rocco; Iuliano, Eleonora; Forte, Iris Maria; Calandruccio, Natale Daniele; Falzea, Antonia Consuelo; Strangio, Alessandra; Nardone, Valerio; Pastina, Pierpaolo; Tini, Paolo; Luce, Amalia; Caraglia, Michele; Caracciolo, Daniele; Mutti, Luciano; Tassone, Pierfrancesco; Pirtoli, Luigi; Giordano, Antonio; Tagliaferri, Pierosandro

Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial cancer. Monoclonal antibodies (mAbs) against either PD-1 or PD-L1 are active agents for these patients; however, their use may be complicated by unpredictable immune-related adverse events (irAEs), including immune-related pneumonitis (IRP). We carried out a retrospective multi-institutional statistical analysis to investigate clinical and biological parameters correlated with IRP rate on a cohort of 256 patients who received real-world treatment with PD-1/PD-L1 blocking mAbs. An independent radiological review board detected IRP in 29 patients. We did not find statistical IRP rate correlation with gender, tumor type, specific PD-1 or PD-L1 blocking mAbs, radiation therapy, inflammatory profile, or different irAEs. A higher IRP risk was detected only in mNSCLC patients who received metronomic chemotherapy +/− bevacizumab compared with other treatments prior PD-1/PD-L1 blockade. Moreover, we detected a strong correlation among the IRP rate and germinal expression of HLA-B*35 and DRB1*11, alleles associated to autoimmune diseases. Our findings may have relevant implications in predicting the IRP rate in mNSCLC patients receiving PD-1/PD-L1 blockade and need to be validated on a larger patient series.